Table 1.
Study population description.
| Demographic (n=131) | |
|
| |
| Age, median (IQR) | 33.9 (24.3–45.9) |
| Patients <15 years old, n (%) | 11 (8) |
| Male, n (%) | 90 (69) |
|
| |
| Epidemiological presentation | |
|
| |
| Environmental exposure n (%) | 110 (84) |
| Environmental and person-to-person Exposure n (%) | 21(6) |
| Number of clusters, n | 15 |
| Cases in cluster, n (%) | 30 (23) |
| Environmental and person-to-person risk, n (%) | 21(70) |
| Person to person risk, n (%) | 3 (10) |
|
| |
| Clinical Course | |
|
| |
| Patients with ≥ 1 previous medical evaluation before hospital admission, n (%)a | 98 (76) |
| N of previous medical evaluation before hospitalization, median (min- max) a | 3 (1–4) |
| Days between symptom onset and hospitalization mean (min-max) | 4.3 (0–17) |
| Severe cases, n (%)b | 77 (59) |
| Only mechanical ventilation, n (%) | 61 (47) |
| ECMO + mechanical ventilation, n (%)c | 16 (24) |
| Case Fatality Rate, n (%) | 23 (17) |
| Hospital length of stay, median (IQR) | 10 (6.5–15.5) |
| Hospital length of stay among fatality cases, median (IQR) | 2 (2–3.23) |
|
| |
| Initial laboratory values at admission | |
|
| |
| Platelets x1000/mL, median (IQR)d | 50 (38–70) |
| Hematocrit %, median (IQR)e | 44.3(40–48.8) |
a
patients with available data, n=129
b
severe cases were those who needed respiratory and cardiac support with mechanical ventilation, ECMO and vaso active drugs.
c
patients with available data since 2018, n=68
d
patients with available data, n=125
e
patients with available data, n=122